BridgeBio Pharma
BBIO
76.03
-2.15
-2.75%
BridgeBio Pharma
US · BBIO
#1254 by market cap
Listed 2019
76.03
-2.15
-2.75%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Quant vs Street three independent views, side by side
StockVane factor grade
C
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Analyst consensus 16 analysts
Buy
Avg price target 110.00 +44.7%
Price target rangecurrent 76.03
Low91.00
Avg110.00
High156.00
Buy 94%
Hold 6%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-20 | Piper Sandler | -- | Buy | 120.00 |
| 2026-11-13 | Morgan Stanley | -- | Buy | 91.00 |
| 2026-11-02 | CCORF | -- | Buy | 108.00 |
| 2026-11-02 | Barclays | -- | Buy | 156.00 |
| 2026-10-30 | Wells Fargo | -- | Buy | 102.00 |
| 2026-10-30 | UBS | -- | Buy | 92.00 |
| 2026-10-30 | Piper Sandler | -- | Buy | 120.00 |
| 2026-10-30 | BofA Securities | -- | Buy | -- |
| 2026-10-30 | Morgan Stanley | -- | Buy | 88.00 |
| 2026-10-30 | Evercore | -- | Buy | 130.00 |
| 2026-10-30 | Citi | -- | Hold | 91.00 |
| 2026-10-30 | RBC Capital | -- | Buy | 100.00 |
| 2026-10-29 | TD Cowen | -- | Buy | 100.00 |
| 2026-10-29 | Cantor Fitzgerald | -- | Buy | 110.00 |
| 2026-10-29 | Wells Fargo | -- | Buy | 102.00 |
| 2026-10-25 | Cantor Fitzgerald | -- | Buy | 110.00 |
| 2026-10-22 | Morgan Stanley | -- | Buy | 87.00 |
| 2026-10-21 | Morgan Stanley | -- | Buy | 87.00 |
| 2026-10-20 | Citi | -- | Hold | 91.00 |
| 2026-10-19 | Piper Sandler | -- | Buy | 120.00 |
| 2026-10-19 | BofA Securities | -- | Buy | 102.00 |
| 2026-10-19 | Citi | -- | Hold | 91.00 |
| 2026-10-16 | UBS | -- | Buy | 92.00 |
| 2026-10-15 | Wells Fargo | -- | Buy | 102.00 |
| 2026-10-15 | UBS | -- | Buy | 92.00 |
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-29 | After close | ±10.15% | +5.97% (in line) |
| 2026/Q2 | 2026-08-10 | After close | ±7.22% | -1.15% (in line) |
| 2026/Q1 | 2026-05-07 | After close | ±7.23% | -0.09% (in line) |
| 2025/Q4 | 2026-02-24 | After close | ±11.04% | -2.59% (in line) |
| 2025/Q3 | 2025-10-29 | After close | ±10.92% | -4.88% (in line) |
| 2025/Q2 | 2025-08-05 | After close | ±14.51% | -8.94% (in line) |
| 2025/Q1 | 2025-04-29 | After close | ±12.86% | +5.33% (in line) |
| 2024/Q4 | 2025-02-20 | -- | ±14.67% | +1.42% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:01:24 · For reference only, not investment advice and not tailored to your situation.
BridgeBio Pharma discussion 0 comments